Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Design and synthesis of backbone cyclic phosphopeptides: the IkappaB model.

Qvit N, Hatzubai A, Shalev DE, Ben-Neriah Y, Gilon C.

Adv Exp Med Biol. 2009;611:139-40. No abstract available.

PMID:
19400129
2.

Design and synthesis of backbone cyclic phosphorylated peptides: The IkappaB model.

Qvit N, Hatzubai A, Shalev DE, Friedler A, Ben-Neriah Y, Gilon C.

Biopolymers. 2009 Feb;91(2):157-68. doi: 10.1002/bip.21098.

PMID:
19025995
3.

Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.

Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y, Alkalay I.

Genes Dev. 2002 May 1;16(9):1066-76.

4.

Pseudosubstrate regulation of the SCF(beta-TrCP) ubiquitin ligase by hnRNP-U.

Davis M, Hatzubai A, Andersen JS, Ben-Shushan E, Fisher GZ, Yaron A, Bauskin A, Mercurio F, Mann M, Ben-Neriah Y.

Genes Dev. 2002 Feb 15;16(4):439-51.

5.

Identification of the receptor component of the IkappaBalpha-ubiquitin ligase.

Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben-Neriah Y.

Nature. 1998 Dec 10;396(6711):590-4.

PMID:
9859996
6.

Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase.

Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, Beyth S, Mercurio F, Manning AM, Ciechanover A, Ben-Neriah Y.

EMBO J. 1997 Nov 3;16(21):6486-94.

7.

Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway.

Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y.

Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10599-603.

8.

Costimulation requirement for AP-1 and NF-kappa B transcription factor activation in T cells.

Jung S, Yaron A, Alkalay I, Hatzubai A, Avraham A, Ben-Neriah Y.

Ann N Y Acad Sci. 1995 Sep 7;766:245-52.

PMID:
7486667
9.

Signalling intermediates of CD28.

Ben-Neriah Y, Alkalay I, Yaron A, Hatzubai A, Jung S.

Res Immunol. 1995 Mar-Apr;146(3):154-8. Review. No abstract available.

PMID:
8525045
10.

In vivo stimulation of I kappa B phosphorylation is not sufficient to activate NF-kappa B.

Alkalay I, Yaron A, Hatzubai A, Jung S, Avraham A, Gerlitz O, Pashut-Lavon I, Ben-Neriah Y.

Mol Cell Biol. 1995 Mar;15(3):1294-301.

11.

Antibodies in human sera against the Epstein-Barr virus encoded latent membrane protein (LMP).

Sulitzeanu D, Szigeti R, Hatzubai A, Dillner J, Hammarskjöld ML, Klein G, Klein E.

Immunol Lett. 1988 Aug;18(4):301-6.

PMID:
2846438
12.

Proteins in normal and malignant cells, cross-reacting with the latent membrane protein encoded by Epstein-Barr virus.

Hatzubai A, Lerner RA, Klein G, Sulitzeanu D.

Eur J Immunol. 1988 Aug;18(8):1283-8.

PMID:
2843380
13.

Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas.

Hatzubai A, Anafi M, Masucci MG, Dillner J, Lerner RA, Klein G, Sulitzeanu D.

Int J Cancer. 1987 Sep 15;40(3):358-64.

PMID:
3040601
14.

Levels of fibrinogen/fibrin degradation fragment E and related substances in sera and effusions of patients with malignant disease.

Gilead Z, Zahavi R, Hatzubai A, Brufman G, Biran S, Sulitzeanu D.

J Cancer Res Clin Oncol. 1983;106(3):195-201.

PMID:
6654954
15.
16.

The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma.

Hatzubai A, Maloney DG, Levy R.

J Immunol. 1981 Jun;126(6):2397-402.

PMID:
6785351

Supplemental Content

Loading ...
Support Center